VRNA News and Press, Verona Pharma plc From 04/10/23

LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has dosed the...

2023-04-04 17:08:18 ET Gainers: Roivant Sciences  ( ROIV ) +5% . Leonardo DRS ( DRS ) +4% . Kura Sushi USA ( KRUS ) +4% . SomaLogic ( SLGC ) +4% . Accolade ( ACCD ) +4% . Losers: Verona Pharma  ( VRNA ) -4...

2023-03-28 12:18:44 ET Summary Lead drug candidate had positive results in 2 Phase 3 trials. If its marketing application is submitted in a timely fashion, it should get reviewed and approved next year. Sales are likely to surpass that of recently approved nebulizer solutions....

2023-03-27 02:31:17 ET Summary Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE trials show significant improvements in lung function, ...

2023-03-15 11:44:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stoc...

2023-03-12 04:00:11 ET Summary Verona Pharma's ensifentrine achieved positive results in a Phase 3 study with an indication for COPD. Ensifentrine is also in Phase 2 studies to address asthma and cystic fibrosis. Long-term estimates have ensifentrine as a potential blockbuster...

2023-03-07 12:03:10 ET Verona Pharma plc (VRNA) Q4 2022 Earnings Conference Call March 07, 2023, 09:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathleen Rickard - Chief Medical Office...

2023-03-07 09:53:47 ET The following slide deck was published by Verona Pharma plc in conjunction with their 2022 Q4 earnings call. For further details see: Verona Pharma plc 2022 Q4 - Results - Earnings Call Presentation

2023-03-07 06:14:49 ET Verona Pharma press release ( NASDAQ: VRNA ): Q4 GAAP EPS of -$0.02 beats by $0.03 . Cash and cash equivalents at December 31, 2022, were $227.8 million (December 31, 2021: $148.4 million). The Company believes cash and cash equivalents at De...

Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 07, 2023 (GLOBE NEWSWIRE...